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how the concept and principles of software engineering and adopting their best 
practices in model development can increase model transparency and our confi-
dence that our models perform as expected. We will also compare the advantages 
and disadvantages of using spreadsheets versus other programming languages. 
Briefly, the primary advantage of the spreadsheet is that it’s universally available 
and accessible to all. It’s universal in that a spreadsheet is available on most com-
puters. It’s accessible in that everyone can open the model, inspect it, and use it. 
Beyond these advantages, the structure of the spreadsheet challenges our model 
code to be intention revealing and transparent. For example, generating an audit 
trail showing the history of what changes were made, when, and by who is not 
possible with spreadsheet files. Moreover, the spreadsheet does not have available 
standard software tools for developing test suites. A test suite represents a series 
of tests that must be passed to confirm software performs as expected. For models, 
this would mean the test suite confirms a model computes what it purports to com-
pute. Hence, test suites serve a critical and foundational function in the lifecycle of 
modern software development and can serve a similar role in pharmacoeconomic 
model development. In summary, adopting traditional programming languages and 
their software engineering support tools offers an opportunity to increase model 
transparency compared with spreadsheets. Reimbursement agencies should con-
sider broadening their software guidances to include non-spreadsheet programming 
languages to increase model transparency and our confidence that pharmacoeco-
nomic models perform as expected.
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The end product of EQ-5D valuation studies is an algorithm describing, on aver-
age, the utility decrements associated with each dimension and level of problems 
within the EQ-5D descriptive system, and potentially a range of interaction effects 
between dimensions and levels. Standard methods for eliciting the preference data 
upon which these algorithms are based (time trade-off, discrete choice experiment, 
standard gamble, visual analogue scale) vary considerably in approach, but have 
in common an aim to ‘uncover’ these preferences by asking survey respondents to 
evaluate a sub-set of EQ-5D health states, and then using their responses to infer 
the relative importance to them of the specific dimensions and levels. An alterna-
tive approach, which has never been explored, is to directly ask people to construct 
their own personal utility functions. Instead of asking people to value a selection of 
EQ-5D states, and to infer their utility functions with respect to EQ-5D dimensions 
and levels from their responses, this approach involves directly asking people about 
the relative importance to them of dimensions, levels and interactions between 
them. In this presentation, we will describe the development of an innovative set 
of questions designed to directly elicit personal utility functions from members of 
the general public. The approach is informed by “swing weighting” techniques in the 
multi-criteria decision analysis literature and by existing direct valuation methods 
such as the short form individual quality of life measure. We will summarise the 
results of a feasibility study which tested the acceptability of the questions, and will 
show how the results can be used to generate EQ-5D values. We will also discuss the 
research that is required to further refine and operationalise the method.
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Objectives: Cardiac rhythm management devices (CRMD’s) have proven their clini-
cal effectiveness for patients with heart rhythm disorders. Little is known about safety 
and complication rates during implantations of these devices. This study demon-
strated the major ant the minor complications related to implantations of CRMD’s, 
and estimated the additional hospital stay and cost associated with managing these 
adverse events. MethOds: During a period of one year in total 464 consecutive recipi-
ents were subjected to CRMD’s implantation and furthermore were recruited and 
followed up for 2 years. Finally, data were analyzed for 398 patients who completed 
the two year’s follow up, resulting in a total of 796 patient-years. Results: From the 
201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients had seven 
adverse events, six major and one minor (5 patients had lead’s dislodgement, 1 of 
them twice (minor adverse events) and 1 patient developed pocket infection (major 
adverse event)), while from the 117 PMs replacements 1 (0,85 %) patient developed 
a major adverse event a pocket erosion. 2 patients with minor adverse event (1 with 
an initial PM and 1 with replacement) died before they complete the follow up from 
reasons unrelated to cardiac causes. There weren’t any adverse event neither in 
initial implantations (69 patients) nor in replacements (11 patients) of implantable 
cardioverter defibrillator (ICD). The average prolongation of the hospital stay was 7 
days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct hospital 
cost. cOnclusiOns: This study provides relatively low rates of adverse events in 
impacts on data analysis/results along with cost impact. As estimated by the Data 
Warehousing Institute, the costs of low quality data exceeds $600 billion annually. 
Data cleaning process includes querying for errors, typos, outliers, out-of-range 
responses, missing data, deviations, etc. Paper: query data for erroneous/out-of 
range values; these values need to be cross-checked with original paper form to 
identify if error is associated with patient entry or data entry staff. If associated with 
patient entry, it may need to be set as missing. When original paper is lost, values 
may need to be set to missing as accuracy cannot be confirmed. Time/dates may be 
out-of-range or missing, which require cross-checking with original paper. If time/
date cannot be confirmed, the entire entry may need to be set as missing. Missing 
values in data need to be identified and cross-checked with original paper to confirm 
if value was skipped by patient or by data entry staff. ePRO: can be implemented to 
prevent entry of out-of range values; includes time/date stamps; patient direct data 
entry eliminates error by data entry staff; can be programmed to not allow skipped 
responses to prevent missing data responses. End-of-study time is precious to the 
pharma industry where results need to be analyzed for submissions. Data cleaning 
with paper can be labor intensive and ePRO can save time with preventing errors 
from occurring, reducing time needed for data cleaning.
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Objectives: The global economic crisis imposes severe restrictions on healthcare 
budgets, limiting the coverage of new interventions, even when they are cost-effec-
tive. Our objective was to develop a tool that can assist decision-makers in compar-
ing the impact of medical intervention alternatives on the entire target population, 
under a pre-specified budget constraint. MethOds: We illustrated the tool by using 
a target population of 1,000 patients, and a budget constraint of $1,000,000. We com-
pared two intervention alternatives: the current practice that costs $1,000 and adds 
0.5 quality-adjusted-life-years (QALYs) per patient and a new technology that costs 
100% more, and provides 20% more QALYs per patient. We also developed a formula 
for defining the maximum premium price for a higher-cost/higher-effectiveness 
intervention that can justify its adoption under a constrained budget. Results: 
Using the new therapy will result in a loss of 300 QALYs, compared to the lower-
cost, lower-effective intervention, despite a favorable incremental cost-effectiveness 
ratio (ICER) of $10,000. The maximum price for the higher-efficacy therapy that 
will preserve the target population outcomes is 20% higher than the lower-cost 
therapy. cOnclusiOns: Although an intervention associated with higher costs 
and higher efficacy may have an acceptable ICER, it could provide inferior outcomes 
in the target population under budget constraints, depending on the relative effec-
tiveness and costs of the interventions. The cost premium that can be justified for 
a higher-efficacy intervention is directly correlated to its effectiveness premium. 
Using the proposed tool may assist decision-makers in improving overall healthcare 
outcomes, especially in times of economic downturn.
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While some have fully embraced and incorporated ePROs/eCOAs into protocol 
designs, many continue to use paper PROs/COAs. This conceptual paper explores rea-
sons for paper PRO/COA continued use, focusing on how PROs can be integrated into 
the electronic trial solution to reduce the burden to patients/participants, sites, and 
clinical teams in setting up, maintaining, and closing out a clinical trial. Associated 
risks and mitigation strategies will be identified in transitioning to ePRO/eCOA 
collection modes. Strategies recommended for successful transition to integrated 
electronic PRO/COA solutions will be discussed. Integration of ePRO/eCOA provides 
several benefits over paper, including improved compliance and higher data quality. 
Comparing the advantages of electronically captured PRO/COA data vs. paper, the 
benefits of ePRO/eCOA far outweigh those of paper. Combine this with the support 
and advocacy of ePRO/eCOA in clinical trials by regulatory authorities and a shift of 
the general population towards electronic devices; it raises the question why all clini-
cal trials are not using ePRO/eCOA to optimize the integrity of data and trial results. 
Common obstacles in the selection of a PRO/COA electronic data collection mode 
include: paper instruments designed for a paper world, inability to determine true 
risks, unknown total cost of electronic vs. paper administration, instrument author 
has sometimes costly requirements for migration, unclear translation expectations, 
and fear of the unknown. An assessment of methods to facilitate the transition to 
electronic data capture will be performed. Examples include use of items/instruments 
that are appropriate for electronic platforms and easily migrated and site and patient 
training plans. In this age of technological advancements, including an integration 
plan in clinical trials is important to mitigate potential risks and minimize the burden 
to clinical trial staff and participants. Detailing this up front can help to alleviate many 
of the obstacles in the transition from paper to electronic PRO/COA.
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The spreadsheet dominates the pharmacoeconomics field as the software platform 
of choice for programming pharmacoeconomic models that are submitted to reim-
bursement agencies worldwide. Arguably, the spreadsheet represents a poor choice 
for model development and implementation as standard software development 
tools to manage spreadsheet quality are non-existent. This paper will demonstrate 
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ultrasound was the most common imaging procedure both 12 months pre- and 
36 months post-index (31.0%, 54.6%, respectively), followed by abdominal/pelvic 
ultrasound (27.3%, 49.6%, respectively). cOnclusiOns: Approximately one-third of 
women with newly diagnosed uterine fibroids underwent hysterectomy within the 
first year of initial diagnosis. Minimally invasive procedures such as hysteroscopic 
myomectomy were infrequently utilized, despite published evidence showing con-
siderably lower costs and complication rates over hysterectomy.
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Objectives: While effectiveness of fibrin sealants for controlling bleeding in car-
diac surgery has been demonstrated, there is a paucity of research on other clinical 
outcomes of fibrin sealants. In this retrospective observational study we analyzed 
the clinical outcomes of two different fibrin sealants in a population of patients 
undergoing cardiac surgical procedures. MethOds: Data from patients undergoing 
coronary artery bypass grafting (CABG), valve and valvular procedures with CABG 
during the years 2008 - 2012 were extracted from Premier’s Hospital Database. The 
Premier Hospital Database is a comprehensive database containing data from over 6 
million US hospital discharges annually. Only surgeries in which a fibrin sealant was 
utilized were included; all other hemostatic agents were excluded from the study. The 
following clinical outcomes were assessed: major and minor complications, transfu-
sions, surgical revisions for bleeding, operative mortality (hospitalization), OR time 
and hospital and ICU length of stay (LOS). Logistic regression analyses were performed 
on categorical outcome variables and GLM regression analyses were performed on 
continuous outcome variables. Study covariates included: age, primary procedure, 
Charlson Co-morbidity Index (CCI) score, heparin use, protamine use, admission type, 
gender, race, teaching hospital, bed size and region. Results: A total of 2,560 inpa-
tient cardiac procedures using fibrin sealant with synthetic aprotinin (FS-apr) were 
compared to 1,019 procedures using fibrin sealant without aprotinin (FS). Results 
suggested that FS-apr was associated with significantly lower rates of minor compli-
cations (21.1% vs. 27.1%, p = 0.002), Day 1 Transfusions (28.6% vs. 36.8%, p = 0.015) and 
ICU LOS (4.7 days vs 7.1 days, p < 0.0001) as compared to FS. No significant differences 
were found between FS-apr and FS on the other clinical outcomes. cOnclusiOns: 
FS-apr was associated with signficantly lower rates of Day 1 Transfusions, avoidable 
minor complications and lower average ICU LOS as compared to FS.
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Objectives: Peripheral Blood Transplant (PBT) accounted for three-quarters of 
the Hematopoietic Cell Transplant (HCT) from unrelated donors in the past dec-
ade, which indicates it has largely replaced Bone Marrow Transplant (BMT) as 
the preferred graft source. This shift occurred due to evidence suggesting faster 
neutrophil and platelet engraftment with the former. However, clinical evidence 
favoring PBT for other outcomes is inconclusive. Although meta-analyses have 
compared outcomes for PBT and BMT from related donors, no such analysis has 
been conducted for unrelated donor procedures. Our objective is to conduct a 
meta-analysis comparing the outcomes in patients undergoing allogeneic unre-
lated donor HCT comparing PBTvs.BMT. MethOds: We conducted a systematic 
literature search(PUBMED,CANCERLIT and Cochrane databases) identifying rand-
omized trials and retrospective studies comparing outcomes of allogeneic unrelated 
donor PBTvs.BMT. We extracted longitudinal transplant outcomes, including acute 
graft-versus-host disease(GVHD) grade II to IV(aGVHD), chronic GVHD(cGVHD), 
overall-survival(OS), transplant-related mortality(TRM), disease-free survival(DFS) 
and relapse from published Kaplan-Meier curves. We used the inverse variance 
method(Cochrane RevMan5.3.5) to estimate pooled hazard ratios(HRs) and 95% con-
fidence-intervals(CI). HR value< 1.00 for an outcome signified PBT as the favorable 
option compared to BMT. Results: One randomized trial and five retrospective 
studies were included in the analysis. PBT was significantly less favorable than BMT 
on aGVHD [HR(1.30),CI(1.15 to 1.47)] and cGVHD [HR(1.32), CI(1.16 to 1.49)]. We did-
not find statistically significant differences in other outcomes:OS [HR(1.02),CI(0.86 
to 1.21)], DFS [HR(1.00),CI(0.91 to 1.10)], Relapse [HR(1.02,CI (0.78 to 1.34)] and TRM 
[HR(0.98),CI(0.77 to 1.24)]. cOnclusiOns: Although PBT is the predominant mode 
of allogeneic HCT, our meta-analysis found no outcomes for which PBT is favorable 
compared to BMT. The only statistically significant comparisons indicated increased 
hazard of acute and chronic GVHD with PBT. While PBT may offer other clinical 
advantages over BMT that merit weight in clinical decision-making, its failure to 
demonstrate significant improvements in overall survival, disease-free survival 
and transplant-related mortality and increased risk of GVHD calls current clinical 
practice into question.
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patients subjected to PMs implantation, initial or replacement, in our center compared 
with others studies. In the case of ICD implantations, initials or replacements, there 
weren’t any adverse event. The additional hospitalization days and cost attributed 
to these adverse events depends on the nature of adverse event.
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Objectives: Research on prognostic factors of ventricular arrhythmias inducibility 
in patients with severe reduced LV systolic function being ICD candidates for primary 
prevention of sudden cardiac death has given limited results so far. Aim of our study 
was to examine the relationship of specific echocardiographic markers, beyond LV 
ejection fraction, particularly left ventricular hypertrophy and left ventricular end-
diastolic diameter, with ventricular arrhythmias inducibility during electrophysiologi-
cal study in patients with ischemic cardiomyopathy. MethOds: Data were acquired 
from patients with ischemic cardiomyopathy and severe reduced LV systolic function 
who underwent electrophysiological in the context of primary prevention of sud-
den cardiac death. Electrophysiological study protocol included programmed elec-
trical stimulation from right ventricular apex. Results: Of 119 patients included, 
ventricular arrhythmias were induced in 76 (63.9%). Prior echocardiographic study 
revealed 26 (21%) patients with ventricular hypertrophy (defined as interventricular 
septum and posterior wall diastolic thickness > 11mm) and 90 patients (76.3%) with 
dilated left ventricle (defined as LV end-diastolic diameter > 55 mm). 80% of patients 
with left ventricular hypertrophy had ventricular arrhythmias induced compared 
to 59% of patients without ventricular hypertrophy (p< 0.05). However, as regards 
LV end-diastolic diameter, difference between groups was not statistically signifi-
cant (p= 0.92). cOnclusiOns: In populations at high risk for sudden cardiac death, 
such as ischemic cardiomyopathy patients, ventricular hypertrophy is correlated to 
ventricular arrhythmias inducibility and possibly is a risk factor for spontaneous 
malignant arrhythmias.
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Objectives: To compare QFT-GIT to TST in detection of latent TB infection among 
National Guard general population in Saudi Arabia. MethOds: a total of 1369 subjects 
chosen randomly from the catchment areas of PHC centers of national Guard Health 
Affairs in Saudi Arabia. inclusion criteria were Saudi national, age 5 years or more, 
resident of Saudi Arabia and availability during the study. Exclusion criteria included 
age less than 5 years (to avoid the BCG vaccination effect on the results ), present or 
previous active tuberculosis, those already diagnosed of having LTBI &/ or on anti TB 
prophylaxis & all immunocompromised conditions. Blood was drawn and processed 
using QFT-GIT followed by immediate administration of TST solution on subjects fore-
arm. Data were collected and analyzed using SPSS software. Results were compared 
using the chi-square test & kappa coefficient was calculated. Results: both tests 
had a significant overall agreement of 88.8% (k= 0.332; p< 0.001). Negative concordance 
represented 85.2% and positive concordance represented 3.6% . Positive QFT-GIT but 
negative TST was 5.5% of the results while positive TST but negative QFT-GIT was 
5.7% of the results. Concordance was associated significantly with younger ages and 
female gender. Positive results in both tests were significantly associated with older 
ages and male gender only in 15-44 years age group. cOnclusiOns: The overall 
agreement of TST & QFT-GIT among Saudi National Guard general population was 
88.8% for detection of LTBI. In absence of a gold standard, QFT-GIT showed acceptable 
results compared to TST for detecting LTBI in intermediate TB burden country with 
at birth BCG highly vaccinated population.
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Objectives: To describe treatment patterns and diagnostic pathways for women 
with uterine fibroids up to three years following a new diagnosis. MethOds: 
Patients with a new diagnosis of uterine fibroids (ICD-9 code: 218.9) were identi-
fied in the Truven Health MarketScan Research Databases from 2004-2013. The use 
of specific diagnostic and treatment procedures and medications were described 
in the 12 months prior to (pre-index) and in the 12, 24 and 36 months following 
(post-index) the diagnosis (index event). Patients were required to have continuous 
enrollment throughout the pre- and post-index periods. Results: A total of 359,672 
patients met the selection criteria with mean age 46.1 years (SD= 9.3) at first diag-
nosis. Of those, subsets of 244,827 (68.1%) patients and 164,645 (45.8%) patients had 
24 and 36 months of post-index follow-up, respectively. Hysterectomy was the most 
common surgical intervention, increasing from 29.3% in the first 12 months to 35.5% 
in the first 36 months; average time to hysterectomy was 49.7 days. Other surgical 
interventions used within the first 12 months of follow-up included: endometrial 
ablation (5%), curettage (3.6%), and either hysteroscopic myomectomy, laparascopic 
myomectomy, abdominal myometcomy, or uterine emobolization (< 2% each). 13.1% 
of women used hormonal birth control with higher rates among younger women. 
IUDs or Gnrh agonists were used by approximately 1% of women. Transvaginal 
